The revenue for Iovotibeglogene Autotemcel is expected to reach an annual total of $478 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Iovotibeglogene Autotemcel Overview

Lovotibeglogene autotemcel (bb1111) is under development for the treatment of sickle cell disease (SCD). It is administered through intravenous route as suspension. The therapeutic candidate comprises autologous CD34 positive hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human BA-T87Q-globin gene.

bluebird bio Overview

bluebird bio is a biotechnology company that focuses on the development and commercialization of gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as lentiviral gene addition platform, cancer immunotherapy and gene editing. Its product pipeline includes elivaldogene autotemcel for the treatment of cerebral adrenoleukodystrophy (CALD); betibeglogene autotemcel for transfusion-dependent beta thalassemia; Lovo-cel for the treatment of sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with pharmaceutical companies to discover, develop and commercialize gene therapy products. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

The company reported revenues of (US Dollars) US$3.6 million for the fiscal year ended December 2022 (FY2022), a decrease of 1.8% over FY2021. The operating loss of the company was US$287.1 million in FY2022, compared to an operating loss of US$590.9 million in FY2021. The net loss of the company was US$266.6 million in FY2022, compared to a net loss of US$819.4 million in FY2021.

For a complete picture of Iovotibeglogene Autotemcel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.